Overview Dividends

(OABI) OmniAb - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68218J1034

Antibody Discovery Platform, Transgenic Animals, Bispecific Tools, AI Suite

OABI EPS (Earnings per Share)

EPS Growth (3Y CAGR): -23.66%
EPS Trend (3Y Correlation): -57.3%

OABI Revenue

Revenue Growth (3Y CAGR): -18.80%
Revenue Trend (3Y Correlation): -56.8%

Description: OABI OmniAb October 28, 2025

OmniAb, Inc. (NASDAQ: OABI) commercializes a suite of transgenic-animal and AI-driven platforms that generate fully human or humanized antibodies for partner drug-discovery programs across the United States, Europe, Japan, China, and Canada. Its core technologies-OmniRat, OmniChicken, OmniMouse, plus specialized bispecific (OmniFlic, OmniClic), cow-inspired (OmniTaur), single-domain (OmnidAb), and in-silico (OmniDeep) platforms-are designed to expand the diversity and developability of therapeutic candidates, while a partnership with mAbsolve Ltd. adds Fc-silencing capability to its pipeline.

Key operational metrics (as of the latest 10-Q) show ≈ $35 million in cash and marketable securities, a burn rate of roughly $12 million per quarter, and a licensing revenue run-rate of $4–5 million annually, reflecting a growing client base that now includes > 30 pharma/biotech partners. The broader antibody-discovery market is projected to grow at a CAGR of 12-14 % through 2030, driven by increasing demand for bispecific and next-generation modalities, which aligns with OmniAb’s strategic focus on bispecific (OmniFlic/OmniClic) and cow-derived antibodies (OmniTaur). However, the company remains unprofitable and its valuation is highly sensitive to partnership conversion rates and the timing of downstream milestones.

For a deeper quantitative assessment of OABI’s valuation relative to peers, consider exploring the analytics on ValueRay.

OABI Stock Overview

Market Cap in USD	223m
Sub-Industry	Biotechnology
IPO / Inception	2022-11-02

OABI Stock Ratings

Growth Rating	-81.4%
Fundamental	30.4%
Dividend Rating	-
Return 12m vs S&P 500	-73.3%
Analyst Rating	4.75 of 5

OABI Dividends

Currently no dividends paid

OABI Growth Ratios

Growth Correlation 3m	-49%
Growth Correlation 12m	-80.7%
Growth Correlation 5y	-77.3%
CAGR 5y	-22.56%
CAGR/Max DD 3y (Calmar Ratio)	-0.28
CAGR/Mean DD 3y (Pain Ratio)	-0.67
Sharpe Ratio 12m	-1.20
Alpha	-86.16
Beta	0.931
Volatility	60.19%
Current Volume	883.5k
Average Volume 20d	386.3k
Stop Loss	1.2 (-13%)
Signal	0.01

Piotroski VR‑10 (Strict, 0-10) 2.5

Net Income (-63.5m TTM) > 0 and > 6% of Revenue (6% = 1.38m TTM)

FCFTA 0.10 (>2.0%) and ΔFCFTA 23.44pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 151.9% (prev 244.8%; Δ -92.86pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.11 (>3.0%) and CFO -31.5m > Net Income -63.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 3.77 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (106.1m) change vs 12m ago 4.62% (target <= -2.0% for YES)

Gross Margin 30.69% (prev 4.08%; Δ 26.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 7.28% (prev 6.44%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -15.38 (EBITDA TTM -53.2m / Interest Expense TTM 3.11m) >= 6 (WARN >= 3)

Altman Z'' -5.96

(A) 0.12 = (Total Current Assets 47.6m - Total Current Liabilities 12.6m) / Total Assets 295.7m

(B) -0.46 = Retained Earnings (Balance) -135.5m / Total Assets 295.7m

(D) -4.03 = Book Value of Equity -135.5m / Total Liabilities 33.6m

Total Rating: -5.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 30.37

1. Piotroski 2.50pt = -2.50

2. FCF Yield 13.91% = 5.0

3. FCF Margin data missing

4. Debt/Equity 0.08 = 2.50

5. Debt/Ebitda -0.07 = -2.50

6. ROIC - WACC (= -27.16)% = -12.50

7. RoE -22.79% = -2.50

8. Rev. Trend -56.76% = -4.26

9. EPS Trend -57.31% = -2.87

What is the price of OABI shares?

As of November 09, 2025, the stock is trading at USD 1.38 with a total of 883,478 shares traded.
Over the past week, the price has changed by -10.97%, over one month by -16.36%, over three months by -26.60% and over the past year by -69.54%.

Is OmniAb a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, OmniAb (NASDAQ:OABI) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 30.37 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OABI is around 0.95 USD . This means that OABI is currently overvalued and has a potential downside of -31.16%.

Is OABI a buy, sell or hold?

OmniAb has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy OABI.

Strong Buy: 6
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the OABI price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	8.5	515.9%
Analysts Target Price	8.5	515.9%
ValueRay Target Price	1.1	-22.5%

OABI Fundamental Data Overview November 04, 2025

Market Cap USD = 223.1m (223.1m USD * 1.0 USD.USD)
P/S = 9.69
P/B = 0.8844
Beta = 0.931
Revenue TTM = 23.0m USD
EBIT TTM = -47.8m USD
EBITDA TTM = -53.2m USD
Long Term Debt = 21.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.84m USD (from shortTermDebt, last quarter)
Debt = 21.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.50m USD (from netDebt column, last quarter)
Enterprise Value = 203.3m USD (223.1m + Debt 21.8m - CCE 41.6m)
Interest Coverage Ratio = -15.38 (Ebit TTM -47.8m / Interest Expense TTM 3.11m)
FCF Yield = 13.91% (FCF TTM 28.3m / Enterprise Value 203.3m)
FCF Margin = 122.8% (FCF TTM 28.3m / Revenue TTM 23.0m)
Net Margin = -275.8% (Net Income TTM -63.5m / Revenue TTM 23.0m)
Gross Margin = 30.69% ((Revenue TTM 23.0m - Cost of Revenue TTM 16.0m) / Revenue TTM)
Gross Margin QoQ = -26.02% (prev 100.0%)
Tobins Q-Ratio = 0.69 (Enterprise Value 203.3m / Total Assets 295.7m)
Interest Expense / Debt = 14.26% (Interest Expense 3.11m / Debt 21.8m)
Taxrate = -0.76% (negative due to tax credits) (119.0k / -15.8m)
NOPAT = -48.1m (EBIT -47.8m * (1 - -0.76%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.77 (Total Current Assets 47.6m / Total Current Liabilities 12.6m)
Debt / Equity = 0.08 (Debt 21.8m / totalStockholderEquity, last quarter 262.1m)
Debt / EBITDA = -0.07 (negative EBITDA) (Net Debt 3.50m / EBITDA -53.2m)
Debt / FCF = 0.12 (Net Debt 3.50m / FCF TTM 28.3m)
Total Stockholder Equity = 278.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.48% (Net Income -63.5m / Total Assets 295.7m)
RoE = -22.79% (Net Income TTM -63.5m / Total Stockholder Equity 278.7m)
RoCE = -15.90% (EBIT -47.8m / Capital Employed (Equity 278.7m + L.T.Debt 21.8m))
RoIC = -17.27% (negative operating profit) (NOPAT -48.1m / Invested Capital 278.7m)
WACC = 9.89% (E(223.1m)/V(244.9m) * Re(9.45%) + D(21.8m)/V(244.9m) * Rd(14.26%) * (1-Tc(-0.01)))
Discount Rate = 9.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.94%
[DCF Debug] Terminal Value 77.01% ; FCFE base≈28.3m ; Y1≈34.9m ; Y5≈59.5m
Fair Price DCF = 5.46 (DCF Value 785.8m / Shares Outstanding 144.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -57.31 | EPS CAGR: -23.66% | SUE: -0.82 | # QB: 0
Revenue Correlation: -56.76 | Revenue CAGR: -18.80% | SUE: -0.55 | # QB: 0

Additional Sources for OABI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle